Tlwm Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

Tlwm acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,103 shares of the company’s stock, valued at approximately $1,091,000.

Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in shares of AstraZeneca by 57.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 181,601 shares of the company’s stock worth $12,303,000 after acquiring an additional 66,181 shares in the last quarter. Procyon Advisors LLC increased its position in AstraZeneca by 16.3% in the first quarter. Procyon Advisors LLC now owns 24,550 shares of the company’s stock worth $1,663,000 after purchasing an additional 3,438 shares during the last quarter. Janiczek Wealth Management LLC lifted its position in AstraZeneca by 23.1% during the first quarter. Janiczek Wealth Management LLC now owns 980 shares of the company’s stock valued at $66,000 after purchasing an additional 184 shares during the last quarter. Wealthcare Advisory Partners LLC lifted its position in AstraZeneca by 9.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock valued at $416,000 after purchasing an additional 543 shares during the last quarter. Finally, Brookstone Capital Management purchased a new position in shares of AstraZeneca in the 1st quarter worth $315,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AstraZeneca stock traded down $0.90 during midday trading on Thursday, hitting $78.18. The company had a trading volume of 2,796,709 shares, compared to its average volume of 5,608,135. The company has a fifty day simple moving average of $77.14 and a 200 day simple moving average of $70.20. The stock has a market cap of $242.40 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 1.43 and a beta of 0.48. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $80.86.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $11.92 billion. As a group, analysts predict that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on AZN shares. BMO Capital Markets lifted their price target on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Citigroup raised AstraZeneca to a “strong-buy” rating in a research report on Monday. Barclays upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday. Finally, The Goldman Sachs Group initiated coverage on shares of AstraZeneca in a report on Thursday, May 30th. They issued a “buy” rating and a $97.00 target price for the company. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $88.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.